Neeraj Jamwal

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Ltd. is a fast growing fully integrated Indian pharmaceutical company with global presence engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Our core strength lies in developing and manufacturing differentiated pharmaceutical products in-house, which we commercialize through our marketing infrastructure across geographies and relationships with multi-national pharmaceutical companies. Emcure is ranked 12th largest pharmaceutical company (Source: AIOCD Jan MAT 2017) in India in terms of market share based on the domestic sales of pharmaceutical products. Emcure believes that their competitive advantage in the domestic market lies in their established presence in all major therapeutic areas including blood related, cardiology, pain and analgesics, HIV, gynaecology, nephrology, anti-infective, and vitamins, minerals and nutrients products. We have also recently entered the oncology, diabetes & neuroscience therapeutic areas. Emcure has a well-diversified income base thanks to our business in the international markets. Emcure products are currently shipped to over 65 countries. It has subsidiaries in Dubai, Brazil, South Africa, Singapore, Australia, Turkey, Peru and Nigeria and rep offices in Russia, Myanmar, Vietnam, Ghana, Kazakhstan and Morocco and established offices in US, UK and Canada. Emcure is working towards vast expansion in European Markets as well. Emcure's focus our research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules and biosimilars, and novel drug delivery systems. As per the IMS Health India, TSA for March 2016, Emcure is ranked 1st in Gynaecologicals, 1st in Blood related, 2nd in Oncology, 2nd in HIV, 6th in Hepatoprotectives, 10th in Cardiac, 11th in Anti-malarials and 15th in Anti-infectives therapy areas